A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and gemcitabine in patients with advanced solid tumours

To determine the maximum tolerated doses (MTDs) and dose-limiting toxicities (DLTs) of pegylated liposomal doxorubicin (PLD), paclitaxel (PCX) and gemcitabine (GEM) combination administered biweekly in patients with advanced solid tumours. Twenty-two patients with advanced-stage solid tumours were t...

Descripción completa

Detalles Bibliográficos
Autores principales: Bozionelou, V, Vamvakas, L, Pappas, P, Agelaki, S, Androulakis, N, Kalykaki, A, Nikolaidou, M, Kentepozidis, N, Giassas, S, Marselos, M, Georgoulias, V, Mavroudis, D
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2007
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2359662/
https://www.ncbi.nlm.nih.gov/pubmed/17551496
http://dx.doi.org/10.1038/sj.bjc.6603832

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2359662/
https://www.ncbi.nlm.nih.gov/pubmed/17551496
http://dx.doi.org/10.1038/sj.bjc.6603832

Ejemplares similares